Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy
{{output}}
In gastric cancer, available clinical studies focusing on the activated hepatocyte growth factor (HGF)/MET pathway are limited to surgical and often heterogeneous series. MET copy number gain (CNG) and an activating truncation in the HGF promoter (deoxyadenosi... ...
